Novo Nordisk rejoined the ABPI after a two-year suspension linked to promotional concerns. Audits confirmed compliance with ...

A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Key Takeaways Novo Nordisk shares gained Monday as the company said it would present new data on the ability of semaglutide, ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about a ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Novo Nordisk A/S (NYSE: NVO) is facing a class-action lawsuit from investors who allege the pharmaceutical giant misled them about the prospects ...

The American Academy of Dermatology (AAD) meeting last week continued to provide positive news, including from US biotech ...

Alix Steel and Paul Sweeney harness the power of Bloomberg Intelligence to analyze market news and provide in-depth company and industry research.

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.

Novo Stock- Kepler Cheuvreux’s analyst upgrades Novo Nordisk to ‘buy,’ predicting a 24% gain after a 50% drop from its peak.

Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...